Quickly
Socially
Trending
CryptoPune-based Serum Institute of India (SII), which was issued Rs 5 crore compensation notice by a Chennai man who claimed to have developed adverse health after undergoing the vaccine trials, called his allegation absolutely false. SII, in a statement issued in response to his notice, said there was no correlation between his health condition and the experimental vaccine candidate. The 40-year-old business consultant in Chennai was administered with the Oxford-AstraZeneca COVID-19 vaccine during the third phase of trials. In his legal notice sent to all parties involved, the man claimed that he suffered from "serious neurological and psychological issues” after being administered with the vaccine. DCGI had on September 11 directed Serum Institute of India (SII) to suspend any new recruitment in phase 2 and 3 clinical trials of the Oxford COVID-19 vaccine candidate till further orders in the backdrop of pharma giant AstraZeneca pausing the clinical trials in other countries because of "an unexplained illness" in a participant in the study. However, on September 15 it permitted the Serum Institute of India to recommence the trial.
Google Trends
Live Bot